Daenen Katrijn, Tong-Minh Kirby, Liesenfeld Oliver, Stoof Sara C M, Huijben Jilske A, Dalm Virgil A S H, Gommers Diederik, van Gorp Eric C M, Endeman Henrik
Department of Intensive Care, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Department of Viroscience, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
J Clin Med. 2023 Sep 26;12(19):6197. doi: 10.3390/jcm12196197.
The prediction of disease outcomes in COVID-19 patients in the ICU is of critical importance, and the examination of host gene expressions is a promising tool. The 29-host mRNA Inflam-matix-Severity-3b (IMX-SEV-3b) classifier has been reported to predict mortality in emergency department COVID-19 patients and surgical ICU patients. The accuracy of the IMX-SEV-3b in predicting mortality in COVID-19 patients admitted to the ICU is yet unknown. Our aim was to investigate the accuracy of the IMX-SEV-3b in predicting the ICU mortality of COVID-19 patients. In addition, we assessed the predictive performance of routinely measured biomarkers and the Sequential Organ Failure Assessment (SOFA) score as well. This was a prospective observational study enrolling COVID-19 patients who received mechanical ventilation on the ICU of the Erasmus MC, the Netherlands. The IMX-SEV-3b scores were generated by amplifying 29 host response genes from blood collected in PAXgene Blood RNA tubes. A severity score was provided, ranging from 0 to 1 for increasing disease severity. The primary outcome was the accuracy of the IMX-SEV-3b in predicting ICU mortality, and we calculated the AUROC of the IMX-SEV-3b score, the biomarkers C-reactive protein (CRP), D-dimer, ferritin, leukocyte count, interleukin-6 (IL-6), lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), procalcitonin (PCT) and the SOFA score. A total of 53 patients were included between 1 March and 30 April 2020, with 47 of them being included within 72 h of their admission to the ICU. Of these, 18 (34%) patients died during their ICU stay, and the IMX-SEV-3b scores were significantly higher in non-survivors compared to survivors (0.65 versus 0.57, = 0.05). The Area Under the Receiver Operating Characteristic Curve (AUROC) for prediction of ICU mortality by the IMX-SEV-3b was 0.65 (0.48-0.82). The AUROCs of the biomarkers ranged from 0.52 to 0.66, and the SOFA score had an AUROC of 0.81 (0.69-0.93). The AUROC of the pooled biomarkers CRP, D-dimer, ferritin, leukocyte count, IL-6, LDH, NLR and PCT for prediction of ICU mortality was 0.81 (IQR 0.69-0.93). Further validation in a larger interventional trial of a point-of-care version of the IMX-SEV-3b classifier is warranted to determine its value for patient management.
预测重症监护病房(ICU)中新冠肺炎患者的疾病转归至关重要,而检测宿主基因表达是一种很有前景的工具。据报道,29宿主mRNA炎症-严重程度-3b(IMX-SEV-3b)分类器可预测急诊科新冠肺炎患者和外科ICU患者的死亡率。IMX-SEV-3b在预测入住ICU的新冠肺炎患者死亡率方面的准确性尚不清楚。我们的目的是研究IMX-SEV-3b在预测新冠肺炎患者ICU死亡率方面的准确性。此外,我们还评估了常规检测的生物标志物和序贯器官衰竭评估(SOFA)评分的预测性能。这是一项前瞻性观察性研究,纳入了在荷兰伊拉斯姆斯医学中心ICU接受机械通气的新冠肺炎患者。IMX-SEV-3b评分通过扩增PAXgene Blood RNA管中采集的血液中的29个宿主反应基因生成。提供了一个严重程度评分,范围从0到1,疾病严重程度增加。主要结局是IMX-SEV-3b在预测ICU死亡率方面的准确性,我们计算了IMX-SEV-3b评分、生物标志物C反应蛋白(CRP)、D-二聚体、铁蛋白、白细胞计数、白细胞介素-6(IL-6)、乳酸脱氢酶(LDH)、中性粒细胞与淋巴细胞比值(NLR)、降钙素原(PCT)和SOFA评分的曲线下面积(AUROC)。2020年3月1日至4月30日共纳入53例患者,其中47例在入住ICU后72小时内纳入。其中,18例(34%)患者在ICU住院期间死亡,非幸存者的IMX-SEV-3b评分显著高于幸存者(0.65对0.57,P = 0.05)。IMX-SEV-3b预测ICU死亡率的受试者操作特征曲线下面积(AUROC)为0.65(0.48 - 0.82)。生物标志物的AUROC范围为0.52至0.66,SOFA评分的AUROC为0.81(0.69 - 0.93)。用于预测ICU死亡率的综合生物标志物CRP、D-二聚体、铁蛋白、白细胞计数、IL-6、LDH、NLR和PCT的AUROC为0.81(四分位间距0.69 - 0.93)。有必要在一项更大的关于IMX-SEV-3b分类器即时检测版本的干预性试验中进行进一步验证,以确定其对患者管理的价值。